Enzastaurin hydrochloride.: Protein kinase C β inhibitor, antiangiogenic agent

被引：9
|
作者：
Sorbera, L. A. [1 ]
Serradell, N. [1 ]
Bolos, J. [1 ]
Rosa, E. [1 ]
机构：
[1] Prous Sci, Barcelona 08080, Spain
来源：
DRUGS OF THE FUTURE | 2007年 / 32卷 / 04期
关键词：
D O I：
10.1358/dof.2007.032.04.1095514
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Protein kinase C (PKC) overexpression has been linked to several types of cancer, with the PKC beta isoform suspected to be involved in vascular endothelial growth factor (VEGF)-induced tumor development and angiogenesis and in the apoptosis-regulating phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Targeting of PKC beta therefore represents a potentially effective strategy for the treatment of cancer. Enzastaurin (LY-317615) is an acyclic bisindolylmaleimide that potently and selectively inhibits the PKC beta isoform. Enzastaurin displayed anticancer efficacy in several preclinical cancer models and in clinical trials in patients with advanced cancers. It is currently undergoing phase III development for relapsed glioblastoma multiforme and diffuse B-cell lymphoma.
引用
收藏
页码：297 / 309
页数：13
相关论文
共 50 条
  • [31] Enzastaurin, a protein kinase Cβ inhibitor, suppresses signaling through the Rsk and Bad pathways and induces apoptosis in human gastric cancer cells
    Lee, Keun-Wook
    Kim, Sang Gyun
    Kim, Hwang-Phil
    Kwon, Euna
    You, Aran
    Choi, Hyung-Jun
    Park, Jung-Hyun
    Kang, Byeong-Cheol
    Im, Seock-Ah
    Kim, Tae-You
    Bang, Yung-Jue
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3508S - 3508S
  • [32] Enzastaurin, a protein kinase Cβ inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer
    Lee, Keun-Wook
    Kim, Sang Gyun
    Kim, Hwang-Phill
    Kwon, Euna
    Yons, Jiran
    Choi, Hyung-Jun
    Park, Jung-Hyun
    Kang, Byeong-Cheol
    Im, Seock-Ah
    Kim, Tae-You
    Kim, Woo Ho
    Bang, Yung-Jue
    CANCER RESEARCH, 2008, 68 (06) : 1916 - 1926
  • [33] THE SELECTIVE PROTEIN KINASE C BETA II (PKC BETA II) INHIBITOR ENZASTAURIN (ENZA), IS A POTENT INHIBITOR OF ANGIOGENESIS AND LYMPHANGIOGENESIS IN COLORECTAL CANCER (CRC) MODELS
    Ouaret, D.
    Kamsu-Kom, N.
    Bigot, L.
    Poindessous, V
    Boudou, P.
    Dartigues, P.
    Dumont, S.
    Louvet, C.
    de Gramont, A.
    Larsen, A.
    ANNALS OF ONCOLOGY, 2009, 20 : 30 - 30
  • [34] Cediranib -: VEGFR inhibitor, antiangiogenic agent, oncolytic
    Sorbera, L. A.
    Serradell, N.
    Rosa, E.
    Bolos, J.
    Bayes, M.
    DRUGS OF THE FUTURE, 2007, 32 (07) : 577 - 589
  • [35] Development of Fasudil hydrochloride (Eril(R)): A new protein kinase inhibitor
    Sone, T
    JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN, 1996, 54 (09) : 794 - 800
  • [36] Antiangiogenic and anitumor effects of a protein kinase Cβ inhibitor in human T98G glioblastoma multiforme xenografts
    Teicher, BA
    Menon, K
    Alvarez, E
    Galbreath, E
    Shih, C
    Faul, M
    CLINICAL CANCER RESEARCH, 2001, 7 (03) : 634 - 640
  • [37] Protein Kinase C-β Gene Variants, Pathway Activation, and Enzastaurin Activity in Lung Cancer
    Lee, Sang-Haak
    Chen, Tingan
    Zhou, Jun
    Hofmann, Jennifer
    Bepler, Gerold
    CLINICAL LUNG CANCER, 2010, 11 (03) : 169 - 175
  • [38] The selective protein kinase C β inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway
    Querfeld, Christiane
    Rizvi, Mujahid A.
    Kuzel, Timothy M.
    Guitart, Joan
    Rademaker, Alfred
    Sabharwal, Simran S.
    Krett, Nancy L.
    Rosen, Steven T.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 (07) : 1641 - 1647
  • [39] Targeting protein kinase C by Enzastaurin restrains proliferation and secretion in human pancreatic endocrine tumors
    Mole, Daniela
    Gagliano, Teresa
    Gentilin, Erica
    Tagliati, Federico
    Pasquali, Claudio
    Ambrosio, Maria Rosaria
    Pansini, Giancarlo
    degli Uberti, Ettore
    Zatelli, Maria Chiara
    ENDOCRINE-RELATED CANCER, 2011, 18 (04) : 439 - 450
  • [40] Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-β inhibitor
    Green, Lisa J.
    Marder, Philip
    Ray, Chad
    Cook, Carolyn A.
    Jaken, Susan
    Musib, Luna C.
    Herbst, Roy S.
    Carducci, Michael
    Britten, Carolyn D.
    Basche, Michele
    Eckhardt, S. Gail
    Thornton, Donald
    CLINICAL CANCER RESEARCH, 2006, 12 (11) : 3408 - 3415
12345